Concurrent injection of dexamethasone intravitreal implant and anti-angiogenic agent in patients with macular edema: A retrospective cohort study

To evaluate the safety and efficiency in macular edema patients who concurrently received a single injection of a dexamethasone intravitreal implant (DEX, 0.7 mg) and ranibizumab (2.3 mg). A retrospective cohort study was conducted, and medical records from 2012 to 2016 were reviewed. Patients who r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hung-Yu, Lee, Chia-Yi, Huang, Jing-Yang, Yang, Shun-Fa, Chao, Shih-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709006/
https://www.ncbi.nlm.nih.gov/pubmed/29382007
http://dx.doi.org/10.1097/MD.0000000000008868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709006/
https://www.ncbi.nlm.nih.gov/pubmed/29382007
http://dx.doi.org/10.1097/MD.0000000000008868

Ejemplares similares